Mayne Pharma Group (MYX) AGM 2025 summary

Opening remarks and agenda

• The meeting commenced at 10:00 A.M. AEST (Melbourne Time) on 18 June 2025, with board members, executives, and legal counsel present both in person and online.

• Chair Frank Condella introduced the board and executive team, including CEO Shawn Patrick O'Brien and several non-executive directors.

• The agenda focused solely on the proposed acquisition of 100% of shares by Cosette Australia Bidco Pty Ltd via a scheme of arrangement, aiming to improve patient access to life-enhancing medications.

• The meeting was held as a hybrid event, allowing both in-person and virtual participation, with procedures for questions and voting explained.

Shareholder proposals

• The only item of business was the scheme resolution regarding the acquisition by Cosette, subject to court approval.

• Shareholders were eligible to vote if registered as of June 16, 2025, and could participate in person or online.

Overview of voting outcomes

• Proxy results for the scheme resolution: 98.57% of shares voted in favor, 0.95% against, and 0.48% abstained.

• Among holders, 699 voted for, 94 against, 9 abstained, and 60 open proxies recorded.

• Voting was conducted both in person and online, with proxies cast in favor by the Chair.

• Proxy positions and participation metrics were disclosed, with more shareholders participating than in the previous issue.

• Results were to be announced on the ASX after the meeting.